GlassScriptPhysician profile
Khaled Elraie
NPI 1578530457
$2,526.19
in general payments reported to CMS, 2019-2025
21 companies · $50.84 in 2025
The $50.84 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92.29 · 2020: $225 · 2021: $14.75 · 2022: $712 · 2023: $826 · 2024: $606 · 2025: $50.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,483.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,482.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $801.48 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $389.38 | 2022-2024 | Zeposia |
| Celgene Corporation | $200.82 | 2022-2024 | Zeposia |
| Janssen Biotech, INC. | $123.02 | 2022-2023 | Stelara, Simponi Aria, Remicade |
| Endogastric Solutions, INC | $119.55 | 2023 | Esophyx |
| Qol Medical, LLC | $90.05 | 2022-2024 | Sucraid, Sucraid |
| Gilead Sciences, INC. | $86.40 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.34 | 2022-2024 | Xifaxan, Trulance |
| Regeneron Healthcare Solutions, INC. | $85.33 | 2023 | Dupixent |
| Genzyme Corporation | $84.83 | 2023 | |
| Ironwood Pharmaceuticals, INC | $80.13 | 2020-2024 | Linzess |
| Pfizer INC. | $62.97 | 2019-2024 | |
| Allergan, INC. | $49.89 | 2019-2020 | |
| Ardelyx, INC. | $49.51 | 2024 | Ibsrela |
| Daiichi Sankyo INC. | $49.43 | 2022-2023 | Injectafer |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $47.80 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.26 | 2020-2022 | |
| Ferring Pharmaceuticals INC. | $29.94 | 2023 | Rebyota |
| Merck Sharp & Dohme LLC | $24.79 | 2022 | |
| Intercept Pharmaceuticals, INC. | $16.31 | 2024 | |
| Veran Medical Technologies, INC. | $10.96 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khaled Elraie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.